https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-can-delay-onset-type-1-diabetes
Telsey Advisory Group Maintains Outperform on Leslies, Lowers Price Target to $30
Telsey Advisory Group analyst Dana Telsey maintains Leslies (NASDAQ:LESL) with a Outperform and lowers the price target from $38 to $30.
